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In sepsis, toll-like receptor (TLR)-4 modulates the migration of neutrophils to infectious foci, favoring bacteremia and mortality. In ex-
perimental sepsis, organ dysfunction and cytokines released by activated macrophages can be reduced by gastrin- releasing pep-
tide (GRP) receptor (GRPR) antagonist RC-3095. Here we report a link between GRPR and TLR-4 in experimental models and in sepsis
patients. RAW 264.7 culture cells were exposed to lipopolysaccharide (LPS) or tumor necrosis factor (TNF)-α and RC-3095 (10 ng/mL).
Male Wistar rats were subjected to cecal ligation and puncture (CLP), and RC-3095 was administered (3 mg/kg, subcutaneously);
after 6 h, we removed the blood, bronchoalveolar lavage, peritoneal lavage and lung. Human patients with a clinical diagnosis of
sepsis received a continuous infusion with RC-3095 (3 mg/kg, intravenous) over a period of 12 h, and plasma was collected before
and after RC-3095 administration and, in a different set of patients with systemic inflammatory response syndrome (SIRS) or sepsis, GRP
plasma levels were determined. RC-3095 inhibited TLR-4, extracellular-signal–related kinase (ERK)-1/2, Jun NH2-terminal kinase (JNK)
and Akt and decreased activation of activator protein 1 (AP-1), nuclear factor (NF)-κB and interleukin (IL)-6 in macrophages stimu-
lated by LPS. It also decreased IL-6 release from macrophages stimulated by TNF-α. RC-3095 treatment in CLP rats decreased lung
TLR-4, reduced the migration of cells to the lung and reduced systemic cytokines and bacterial dissemination. Patients with sepsis and
systemic inflammatory response syndrome have elevated plasma levels of GRP, which associates with clinical outcome in the sepsis
patients. These findings highlight the role of GRPR signaling in sepsis outcome and the beneficial action of GRPR antagonists in con-
trolling the inflammatory response in sepsis through a mechanism involving at least inhibition of TLR-4 signaling.
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INTRODUCTION
Sepsis remains an important problem
with high rates of morbidity and mortal-
ity, despite modern advances in critical
care management. Sepsis happens when
the initial host response fails to limit the
infection, leading to systemic inflamma-
tion and multiple organ failure (1). Strat-
egies for treating human sepsis, mainly
targeting proinflammatory mediators,
have only had limited success (2).
Increased levels of circulating cyto -
kines and chemokines, and neutrophil
sequestration in the lung, are characteris-
tics of systemic inflammation (3). Re-
duced neutrophil chemotaxis is associ-
ated with illness severity and organ
damage (4,5). Expansion of bacterial in-
fection leads to systemic toll-like receptor
(TLR) activation, and tumor necrosis fac-
tor (TNF) receptors 1 and 2 (TNFR1/R2)
appear to be involved in this process
(6,7). Endotoxin (lipopolysaccharide
[LPS]), a major cell wall component in
gram-negative bacteria, can induce sys-
temic inflammation and is a major patho-
genic element in infection by gram-nega-
tive bacterial (8). Sensing of LPS by
toll-like receptor (TLR)-4 in innate im-
mune cells is vital for host defense
against gram-negative bacteria. Mole-
cules involved in the TLR-4–activated
pathway include the adaptor molecule,
myeloid differentiation primary response
protein 88 (MyD88), interleukin (IL)-1
 receptor–associated kinases and TNF
 receptor–associated factor 6 (9). This
pathway results in activation of several
mitogen-activated protein kinases
(MAPKs), as well as activation of the
transcription factors such as nuclear fac-
tor (NF)-κB and activator protein 1
(AP-1), which contribute to the develop-
ment of septic shock and multiple organ
failure with transcriptional regulation of
inflammatory genes (10). In this context,
TLR-4–defective mice presented neutro -
phil migration to the peritoneal cavity
during sepsis induced by lethal cecal lig-
ation and puncture (CLP) and, as a con-
sequence, are more resistant to sepsis
than controls (11). Given its central role
in the pathogenesis of sepsis, TLR-4 is a
target for the development of novel ther-
apies against sepsis.
Bombesin (BN) is a 14–amino acid
peptide isolated from toad skin (12). BN-
like immunoreactivity using amphibian
BN antibodies was demonstrated in the
central nervous system, mammalian gut
and lung. Gastrin-releasing peptide
(GRP), a BN-like peptide, has been impli-
cated in the pathogenesis of inflamma-
tory conditions (13–19). BN-like receptors
such as gastrin-releasing peptide recep-
tor (GRPR), neuromedin B receptor and
the orphan BN receptor subtype 3 have
been cloned. These receptors are seven
transmembrane-spanning G protein–
 coupled receptors that activate various
intracellular signaling pathways associ-
ated with neutrophil and macrophages
activation by chemokines (20), long
known to attract various inflammatory
cells (21).
We recently demonstrated that the
GRPR antagonist, RC-3095, decreases the
release of proinflammatory cytokines
and improves survival in sepsis by CLP.
In particular, we showed in a CLP model
of sepsis and acute lung injury that RC-
3095 reduces mortality rates by reducing
organ dysfunction and inflammatory in-
filtration and modulating the release of
proinflammatory cytokines by activated
macrophages (22). These findings are
consistent with the involvement of a
GRPR-stimulated inflammatory path-
way in the development of sepsis. Given
that TLRs are important components of
the innate immune response to infection
and evidence indicates that these recep-
tors may play a role in the sepsis patho-
physiology (23), together with the afore-
mentioned critical role of TLR-4, in
particular in neutrophil migration (6,7),
we hypothesize that GRPR stimulation
may exert its inflammatory effects
through a mechanism involving the
TLR-4 signaling pathway. Thus, the
blockade of GRPR can protect against
 severe sepsis.
The aim of this study was to investi-
gate the effects of RC-3095 on TLR-4 ex-
pression and its signaling pathways in
sepsis.
MATERIALS AND METHODS
Animal Experiments
A total of 15 male Wistar rats, 2–3
months old, were used in this study. Rats
were subjected to CLP as described (24).
The rats were randomly divided into
sham-operated, CLP and CLP plus RC-
3095 groups, comprising five animals per
group. RC-3095 (3 mg/kg subcutaneously;
the dose was based on a dose- response
curve previously published) (22) was ad-
ministered immediately after surgery. We
previously demonstrated that RC-3095
alone has no effect in this model (22);
thus, it was not included in the sham-
 operated plus RC-3095 group. Six hours
after surgery (described below), blood,
bronchoalveolar lavage fluid (BALF) and
peritoneal lavages were collected and the
lung tissue was removed. The experimen-
tal procedures with animals were made
in accordance with the National Institutes
of Health (Bethesda, MD, USA) Guide for
Care and Use of Laboratory Animals (25)
and the approval of our institutional eth-
ics committee.
Human Subjects
Role of the infusion of RC-3095 of cy-
tokine level in patients. Twelve patients
(seven men, five women) admitted to an
adult medical intensive care unit (ICU)
with a clinical diagnosis of septic shock
and failure of three or more organs and
who conformed to the consensus confer-
ence criteria (26) were enrolled in the
study. Patients received a continuous in-
fusion with RC-3095 (3 mg/kg) over a
period of 12 h, and plasma samples were
collected in heparin-treated vacuum
tubes before and after RC-3095 adminis-
tration for later determination of IL-6
and IL-10. Eleven patients with similar
clinical characteristics who did not re-
ceive RC-3095 were included as controls.
All procedures involving patients and
healthy volunteers were made in compli-
ance with the Declaration of Helsinki
and National Institutes of Health guide-
lines and were approved by the institu-
tional ethics committee (protocol number
431/2006). All patients or their relatives
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gave informed consent before being in-
cluded in the study.
GRP plasma levels and sepsis severity.
In a different set of subjects, patients con-
secutively admitted to an adult medical
ICU between August 2008 and December
2008 with systemic inflammatory re-
sponse syndrome (SIRS) or sepsis diagno-
sis were screened for enrollment. Septic
patients (n = 30) were classified as having
sepsis, severe sepsis or septic shock, ac-
cording to the consensus conference (26),
by two board-certified internal medicine
specialists. Septic patients were paired to
SIRS patients (n = 29) in relation to age,
sex, severity scores and mortality (demo-
graphics summarized in Table 1). Patients
were eligible if the time between sepsis
diagnosis (this was done by reviewing
medical charts and/or contacting the pa-
tient’s physician) and ICU admission was
no more than 24 h. Blood was collected at
ICU admission. In parallel, clinically rele-
vant data were recorded daily for 28 d.
Exclusion criteria were as follows: age
below 18 years, neoplasia receiving chem-
otherapy or radiotherapy, chronic hepatic
or renal insufficiency and immunodefi-
ciency. Blood was collected from six
healthy volunteers to serve as the control.
Drugs
The GRPR antagonist RC-3095, origi-
nally synthesized in the laboratory of
one of us (A V Schally) by solid-phase
methods (27), was obtained from Aeterna
Zentaris (Frankfurt am Main, Germany)
and is a highly specific inhibitor of the
GRPR (20).
RAW 264.7 Experiments
Preparations and treatments. RAW
264.7 macrophages were obtained from
UFRJ Cell Bank (Rio de Janeiro, Brazil).
To prepare for reverse-transcription poly-
merase chain reaction (RT-PCR) analysis
of TLR-4 mRNA, immunoblotting of
phosphorylated extracellular- signal-
regulated kinases (pERKs) 1/2, pJNK,
phosphorylated Akt (pAkt), elec-
trophoretic mobility shift assay (EMSA)
of NF-κB and AP-1, and cytokines, the
cells were seeded in 24-well plates (0.5 ×
106 cells/well) and incubated for 24 h in
RPMI-1640 media supplemented with
10% bovine fetal serum. Cultures were
exposed to LPS (Escherichia coli 055:B5;
Sigma Aldrich, St. Louis, MO, USA)
(100 ng/mL) supplemented medium
(RPMI-1640) or RPMI-1640 alone; 4 h
later, RC-3095 (10 ng/mL) was added for
2 h. Times after the treatment period (to
60 min, depending on the experiment set
[see figure legends]), cells and/or media
samples were collected for analysis in
RC-3095–free media. In some experi-
ments, cells were exposed to TNF-α
(Sigma-Aldrich) supplemented medium
(RPMI-1640) or RPMI alone, and 4 h
later, RC-3095 (10 ng/mL) was added for
2 h. Cells and/or samples of the medium
was collected for later analysis.
In Silico Analysis
Interaction networks of compounds
and genes/proteins. To develop a model
network for the interaction between LPS
and RC-3095, different genes/ proteins
involved in LPS-activated and RC-3095
pathways were selected; and then, by
using STITCH 2.0 (28,29), we screened
the possible protein–protein and
 protein–compound interactions on the
basis of experimental knowledge and
the database (confident score 0.7, me-
dium). A list with gene symbols and En-
sembl protein IDs is provided (Supple-
mentary Table S1). The network
connected 45 proteins to LPS and RC-
3095, on the basis of their possible ac-
tions with each other (“binding” and
 “reaction”) and different types of associ-
ations (“experiments,” “homology,”
“databases” and “textmining”) between
each component.
Measurements
TLR-4 mRNA analysis. RNA was ex-
tracted from RAW 264.7 or lungs by
using the TRIZOL reagent (Invitrogen,
Carlsbad, CA, USA). RNA concentra-
tion was determined by absorbance at
260 nm, and RNA integrity was con-
firmed by electrophoresis on 1% agarose
gels and staining with 0.1 mg/L ethid-
ium bromide. After DNAse I digestion
of the total extracted RNA, 1-μg
aliquots of RNA were used to synthe-
size single-strand cDNA by using oligo
dT primer (Promega, Madison, WI,
USA) and Impron II reverse transcrip-
tase (Promega). PCR was carried out
with 1.0 μL RT product serving as the
template. The amplified products were
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Table 1. Patient characteristics.
SIRS Sepsis Severe sepsis Septic shock p
n 29 9 10 11
Age (years) (SD) 59 (15) 60(14) 62(7) 56(15) >0.05
Race
Black 0 1 0 1 >0.05
White 29 8 10 10 >0.05
Sex
Female 11 4 3 5 >0.05
Male 18 5 7 6 >0.05
ICU stay (d) 15 17 13 10 >0.05
Mortality (n) 9 2a 4 10b ≤0.01
APACHE II (SD) 18 (9) 10 (8)a 21 (13)b 24 (10)b ≤0.01
Sepsis source (n)
Abdominal 0 2 3 5 >0.05
Respiratory 0 2 4 3 >0.05
Surgical cut 0 2 1 1 >0.05
Urosepsis 0 1 2 1 >0.05
Skin and soft tissue 0 2 0 1 >0.05
Age, race, sex, ICU length of stay, mortality, APACHE II and sepsis source are quoted as
mean (SD) or number (n). ap ≤ 0.01 versus nonsepsis group; $p ≤ 0.01 versus sepsis group.
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Figure 1. RC-3095 decreased TLR4 mRNA expression, signaling pathways and cytokine/chemokine expression in RAW 264.7 cells exposed
to LPS. Cell cultures were exposed to LPS (100 ng/mL) and, 4 h later, RC-3095 (10 ng/mL) was added for 2 h. Several times after this period,
cells and/or media samples were collected for analysis in RC-3095–free media. (A) RT-PCR, using specific primers to TLR-4, demonstrated
that 2-h RC-3095 treatment of LPS-activated RAW 264.7 cells (collected 30 min after RC-3095 treatment) reduced TLR-4 mRNA levels (ex-
pressed as the ratio of signal intensity to that of coamplified GAPDH: TLR-4 mRNA/GPDH) (*p < 0.05 versus control and $p < 0.05 versus
LPS without RC-3095). (B) RAW 264.7 macrophages were stimulated with LPS; and 30 min after RC-3095 was added, LPS increased NF-κB
and AP-1 DNA-binding activity measured by EMSA; and this was attenuated by RC-3095 treatment (*p < 0.05 versus untreated, 
$p < 0.05 versus LPS). (C–E) Western blot experiments showed that RC-3095 treatment also resulted in a sustained (0–60 min) reduction of
pERK1/2, phosphorylated JNK and phosphorylated Akt levels (*p < 0.05, **p < 0.001 and ***p < 0.0001 versus untreated; 
ap < 0.05 versus LPS). (F) ELISA showed that RC-3095 attenuated MCP-1 and IL-6 increases induced by LPS stimulation in RAW 264.7 cells
(G) and in peritoneal macrophages 30 min after the end of treatment (*p < 0.05 versus control and $p < 0.05 versus LPS).
analyzed by ethidium bromide–stained
agarose gel electrophoresis. The PCR
primer sequences for TLR-4 were 
5′ GGCAG CAGGT GGAAT TGTAT 3′
(sense) and 5′ AGGCC CCAGA GTTTT
GTTCT 3′ (antisense) and 5′ AAGAG
CTGGA ATACC TGGAC 3′ (sense) and
5′ GAAAT GCTAC AGTGG CTACC 3′
(antisense) for cell extracts. The gel 
was analyzed using Gene Flash and
Software Image Gene Tools (Syngene).
TLR-4 mRNA levels were expressed as
the ratio of signal intensity for the tar-
get genes in relation to that for coam-
plified glyceraldehyde-3-phosphate
 dehydrogenase.
NF-κB or AP-1 content. The protein
content of RAW 264.7 cell nuclear ex-
tracts was prepared as described previ-
ously (30). EMSA was performed using
biotin-labeled oligonucleotides to mea-
sure NF-κB or AP-1 content according to
the kit manufacturer’s protocol (Pierce).
Phosphorylation of ERK1/2, JNK and
Akt. Phosphorylation was measured by
Western blotting, wherein whole cell
lysates (20 μg for pERK1/2, phospho-
JNK and phospho-Akt) were separated
by 10% sodium dodecyl sulfate–polyacry-
lamide gel electrophoresis (SDS-PAGE)
and then electro-transferred to nitrocellu-
lose membranes (Amersham Interna-
tional, Buckinghamshire, UK). The mem-
branes were pre-incubated for 1 h at
room temperature in Tris-buffered saline
(pH 7.6) containing 0.05% Tween 20 and
3% bovine serum albumin. The nitrocel-
lulose membranes were incubated with
pERK1/2, phosphorylated JNK and
phosphorylated Akt, and the immunore-
active bands were detected by incubation
with HRP conjugates of anti-rabbit im-
munoglobulin G and enhanced with
chemiluminescence reagents (Amer-
sham).
Cytokine/chemokine level determina-
tion. The concentrations of IL-6, IL-10
and monocyte chemotactic protein
(MCP)-1 were determined by a standard
sandwich enzyme-linked immunosor-
bent assay (ELISA), by using commer-
cially available kits (R&D Systems, Min-
neapolis, MN, USA).
TLR-4, NF-κB and MyD88 levels. Pro-
tein content of TLR-4, NF-κB and MyD88
was also quantified by immunoblotting.
The samples or nuclear extracts (to deter-
mine NF-κB) were pooled, minced
coarsely and homogenized in extraction
buffer (1% Triton-X, 100 mmol/L Tris,
pH 7.4, containing 100 mmol/L sodium
pyrophosphate, 100 mmol/L sodium
 fluoride, 10 mmol/L ethylenediamine -
tetraacetic acid [EDTA], 10 mmol/L
sodium vanadate, 2 mmol/L phenyl-
methylsulfonyl fluoride [PMSF] and
0.1 mg aprotinin/mL) at 4°C. The ex-
tracts were centrifuged at 8,000g and 4°C
for 40 min, and the supernatants were
used for protein quantification (31). Ex-
tracted proteins were denatured by boil-
ing in Laemmli (32) sample buffer con-
taining 100 mmol/L dithiothreitol; run
on SDS-PAGE and transferred to nitro-
cellulose membranes and blocked;
probed with anti-TLR, anti-p65 and anti-
MyD88 antibodies (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA); and de-
veloped (33). The blots were exposed to
preflashed Kodak XAR film with Cronex
Lightning Plus intensifying screens
at –80°C for 12–48 h. Band intensities
were quantitated by optical densitometry
(Scion Image Software; Scion Corpora-
tion, Frederick, MD, USA) of the devel-
oped autoradiographs.
Neutrophil migration in BALF. Mi-
grating neutrophil cell counts in the
BALF were performed as previously de-
scribed (34). The results are expressed as
the number of cells/mm3.
Bacterial counts in the peritoneal exu-
date and blood. Bacterial count was deter-
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Figure 2. Model for RC-3095 and LPS interactions through signaling pathways of common
cellular components. In silico analyses on the basis of the experimental data and data-
base are depicted as action- and association-type interactions. This interaction network
resulted from the interaction of 45 genes/proteins (Supplementary Table S1) with RC-3095
and LPS (confident score 0.7, medium). The shortest association path between RC-3095
and LPS is shown in the insert.
mined as previously described (35). Briefly,
after peritoneal lavage with sterile phos-
phate-buffered saline and blood collection,
aliquots of serial dilutions of the samples
were plated on Mueller-Hinton agar dishes
(Difco; BD, Franklin Lakes, NJ, USA) and
incubated at 37°C; colony-forming units
(CFUs) were counted after 24 h. The results
were expressed as CFU/mL.
Plasma GRP concentrations. Plasma
GRP was determined by ELISA commer-
cial assays according to the manufac-
turer’s instructions (Phoenix Pharmaceu-
ticals, Burlingame, CA, USA).
Statistical Analysis
Results are expressed as means ± stan-
dard deviation (SD). Cell culture results
represent data from three different ex-
periments with three samples in each ex-
periment. Because of the low number of
 animals/cell samples in each experi-
ment, analyses were performed using
the Kruskal-Wallis test or Wilcoxon test
depending on the number of groups. In
the human experiments, demographic
and clinical characteristics of the study
groups were compared by t test, chi-
square test or analysis of variance (one-
or two-way), followed by a Tukey or
Bonferroni post hoc test, as appropriate.
A two-sided significance level of ≤0.05
was considered statistically significant.
Acute Physiology and Chronic Health
Evaluation II (APACHE II) and Sequen-
tial Organ Failure Assessment (SOFA)
scores and sepsis severity were entered
in the Cox regression analysis to esti-
mate the independent association of
each covariate with GRP levels. We
could not enter more variables in the re-
gression because of the low number of
events. Survival curves were constructed
by the Kaplan-Meier method and
 compared with the log-rank test. The
 accuracy of GRP concentrations in dis-
tinguishing between survivors and non -
survivors was examined separately by
receiver operator characteristic (ROC)
curves. All statistical analyses were per-
formed with SPSS 17.0 for Windows
(SPSS, Chicago, IL, USA).
All supplementary materials are available
online at www.molmed.org.
RESULTS
GRPR Antagonist RC-3095 Inhibits
Expression of TLR-4 and Constituent
Molecules of Its Signaling Pathway
and Decreases Cytokine/ Chemokine
Secretion in LPS-Stimulated RAW 264.7
Cells
RT-PCR experiments in RAW 264.7
cultures revealed that RC-3095 signifi-
cantly reduced TLR-4 mRNA levels in
macrophages after LPS exposure (Fig-
ure 1A, F = 16.4, p = 0.001). Subsequent
experiments with EMSA showed that the
nuclear extract from LPS-stimulated
RAW 264.7 cells had a significant in-
crease in the DNA-binding activity of
NF-κB and AP-1 (Figure 1B; F = 235, p <
0.001, to AP-1 and F = 85, p < 0.001, to
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Figure 3. Acute administration of RC-3095 decreased TLR4 mRNA expression, TLR4 and nu-
clear content of p65 level in lung in rats subject to lethal sepsis. Male Wistar rats were sub-
jected to CLP and were divided (n = 5 per group) into sham-operated, CLP and CLP plus
RC-3095 groups. RC-3095 (3 mg/kg subcutaneously) was administered immediately after
surgery. Six hours after surgery, BALF was collected and lung tissue was removed. (A) RT-PCR
experiments showed that TLR-4 mRNA levels (reported as TLR-4 mRNA/GPDH) were in-
creased in CLP rats (*p < 0.05 versus sham), and this was reversed in CLP rats treated with
RC-3095 ($p < 0.05 versus CLP). (B–D) Immunoblot experiments showed that CLP produced
increased TLR-4 and nuclear content of p65 protein levels in lung tissue extracts (*p < 0.05
versus sham) and that RC-3095 treatment decreased this increase ($p < 0.05 versus CLP)
but did not show significant differences in MyD88. Scanning densitometry results are ex-
pressed as arbitrary units. Bars represent means ± SD of five rats. IB, immunoblot.
NF-κB). However, this binding activity
was suppressed by exposure to RC-3095,
suggesting that suppression of NF-κB
and nuclear translocation of AP-1 by
RC-3095 was associated with decreased
gene expression of TLR-4 and MAP ki-
nase activation (Figure 1C, F = 54 [group
versus time], F = 442 [group versus re-
sult], F = 135 [time versus result], p <
0.001 to all interactions; Figure 1D, F =
7.6 [group versus time], F = 31 [group
versus result], F = 17 [time versus re-
sult], p < 0.001 to all interactions; and
Figure 1E, F = 0.04, p = 1.0 [group versus
time], F = 277 [group versus result], p <
0.001, F = 0.04 [time versus result], p =
1.0). ELISAs revealed elevated MCP-1
and IL-6 levels in RAW 264.7 and peri-
toneal macrophages exposed to LPS
(Figure 1F, F = 1,119, p < 0.001, and Fig-
ure 1G, F = 55, p < 0.001) relative to un-
exposed control cells. Administration of
RC-3095 resulted in a significant de-
crease in MCP-1 and IL-6 titers com-
pared with the corresponding levels in
LPS-exposed cells.
Since the blockade of GRP signaling al-
tered the activation of several different in-
tracellular kinases associated with TLR4
activation, we performed an in silico analy-
sis on the interaction of GRP and TLR4
signaling. This analysis gave rise to a net-
work that interconnected 45 genes/
 proteins with RC-3095 and LPS (Supple-
mentary Table S1). On the basis of experi-
mental data, database and textmining rela-
tionships, the RC-3095/ LPS network
shows the interactions between the com-
ponents of cell signaling pathways trig-
gered these components (Figure 2). Our
analysis shows direct interaction of RC-
3095 only with GRPR and GRP, and LPS is
connected with the network at first level
by interaction with TLR4 and the lympho-
cyte antigen 96 (LY96). The shortest path
linking RC-3095 to LPS connects both GRP
and TLR4 to JUN (jun proto-oncogene),
which suggests JNK as the first upstream
point in the cross-talk between GRP and
TLR4 signaling and indicates that effects
of RC-3095 on TLR4 activation are mainly
secondary to JNK inhibition. Besides, the
cross-talk between these two pathways is
evidenced by interactions at downstream
levels. Components common to both path-
ways include proinflammatory components
(such as IL10, TNF, IL6ST and IL6R), mem-
bers of the MAPK pathway (such as MAPK3
and MAPK8) and NF-κB and AP-1–related
components (such as RELA, IKBKB and
FOS), which are connected at several lev-
els to components directly linked to GRP
and TLR4.
RC-3095 Inhibits Expression of TLR-4
and Nuclear Content of p65 in the
Lung in an Animal Model of
Polymicrobial Sepsis
RT-PCR using TLR-4–specific primers
demonstrated high levels of TLR-4
mRNA expression in lung tissue 6 h after
sepsis and significantly reduced expres-
sion of TLR-4 mRNA in RC-3095–treated
animals relative to that in the sepsis group
(Figure 3A, F = 130, p < 0.001). Im-
munoblotting experiments showed that
the decreased mRNA levels in the lung
were followed by decreased TLR-4 protein
levels (Figure 3B, F = 100, p < 0.001) and nu-
clear content of p65 (Figure 3C, F = 129, p <
0.001), but not significant differences in
MyD88 (Figure 3D, F = 3, p = 0.07). Thus,
pharmacological blockade of the GRP-
GRPR system decreased TLR-4 expression
and protein content both in vitro and in vivo.
RC-3095 Decreases Cytokine/
Chemokine Content in an Animal
Model of Polymicrobial Sepsis, Cell
Migration to the Lung and Bacterial
Dissemination
ELISAs revealed elevated MCP-1 and
IL-6 levels in the serum and BALF of
CLP septic rats (Figure 4A, F = 249, p <
0.001, to MCP-1 and F = 68, p < 0.001,
and Figure 4B, F = 155, p < 0.001, to
MCP-1 and F = 417, p < 0.001, to IL-6),
relative to sham control rats. Administra-
tion of RC-3095 resulted in a significant
decrease in MCP-1 and IL-6 titers com-
pared with CLP septic rats. In addition,
RC-3095 decreased the number of leuko-
cytes in the BALF of CLP animals com-
pared with those in untreated CLP ani-
mals (Figure 4C, F = 162, p < 0.001), but
maintained the control of infection, since
there was a reduced bacterial dissemina-
tion in circulation and in peritoneal exu-
dates compared with levels in untreated
CLP animals (data not shown).
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Figure 4. RC-3095 attenuated cytokine/
chemokine production and cell inflamma-
tory migration in lung of CLP animals. Male
Wistar rats were subjected to CLP and
were divided (n = 5 per group) into sham-
operated, CLP and CLP plus RC-3095
groups. RC- 3095 (3 mg/kg subcuta-
neously) was administered immediately
after surgery. Six hours after surgery, BALF
and serum were collected. (A) ELISA
showed that RC-3095 attenuated MCP-1
and IL-6 increases induced by CLP in
serum (B) and BALF. Results are expressed
as means ± SD (*p < 0.05 versus sham and
$p < 0.05 versus CLP). (C) Inflammatory cell
migration in the BALF was decreased in
RC-3095–treated animals. Results are ex-
pressed as means ± SD (*p < 0.05 versus
saline and $p < 0.05 versus CLP).
Plasma GRP Levels Can Be Related to
Outcome in Septic Patients
The clinical profiles of sepsis patients
at all levels of severity (n = 30) were
compared with levels of patients with
SIRS (n = 29). The data were further ana-
lyzed for differences among sepsis pa-
tients according to disease severity: sep-
sis (n = 9), severe sepsis (n = 10) and sep-
tic shock (n = 11) patients. The patient
groups were similar in terms of race, age,
sex, ICU length of stay, sepsis source and
SOFA score (data not shown). The me-
dian APACHE II score of the mild-to-
moderate sepsis group was lower than
the scores of the septic shock, severe sep-
sis and SIRS groups (Table 1). Plasma
GRP concentrations, sampled on the pa-
tients’ first day in ICU, were similar be-
tween the SIRS patients and sepsis pa-
tients (sepsis, severe sepsis and septic
shock combined; Figure 5A, t = 1.5, p =
0.12), but higher when compared with
healthy individuals (4.1 + 1.8 pg/mL, p =
0.02). Comparing patients across levels of
sepsis severity, we found that patients
with septic shock had greater GRP con-
centrations than patients with sepsis or
severe sepsis (Figure 5B, F = 4.6, p =
0.019). Clinical outcome measures re-
vealed that subjects with the highest
GRP concentrations had the highest mor-
tality of the sepsis groups (Figure 5C, t =
5.8, p < 0.001); this association was not
apparent in patients with SIRS (Fig-
ure 5D, t = 0.24, p = 0.8). Patients with a
GRP concentration <10 pg/mL showed
no mortality, whereas patients with a
GRP concentration ≥10 pg/mL showed a
mortality rate of approximately 87% (Fig-
ure 5E, χ2 = 22, p < 0.001, and Figure 5,
χ2 = 4.7, p < 0.02), with an area under the
ROC curve of 0.85. This cutoff value pre-
sented a sensitivity of 100% and a speci-
ficity of 86%. In the Cox regression
analyses, GRP level is not independently
associated with outcome only in the sep-
tic patients (p = 0.68), but it was indepen-
dently associated with mortality when
including SIRS and septic patients in the
regression (p = 0.021).
RC-3095 Decreases Plasma IL-6 Levels
in Septic Patients
Continuous infusion of RC-3095
(3 mg/kg) for 12 h decreased plasma lev-
els of IL-6 in septic patients (Figure 6A,
t = 5.4, p ≤ 0.001), but did not signifi-
cantly affect plasma levels of IL-10 (Fig-
ure 6B, t = 1.9, p = 0.07).
RC-3095 Effects on TLR-4 Independent
Inflammatory Pathways
Because some of the effects mediated
by RC-3095 could be mediated by path-
ways independent of TLR-4 activation,
we determined the effects of GRPR an-
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Figure 5. GRP plasma levels were elevated in human patients diagnosed with sepsis and
correlated with outcome. Patients consecutively admitted to adult medical ICU with SIRS
(n = 29) or sepsis diagnosis (n = 30) were screened for enrollment. Septic patients were
classified as sepsis, severe sepsis or septic shock, and blood was collected in these pa-
tients at ICU admission to determine GRP level by ELISA. (A) When severity of sepsis was
not determined, no difference between GRP levels was observed between SIRS and sep-
sis patients (p < 0.05). (B) Comparison between the severity levels of sepsis (sepsis, severe
sepsis and septic shock) revealed greater plasma GRP levels in the septic shock group rel-
ative to the other two groups (*p < 0.05). (C) Plasma GRP concentrations differed be-
tween sepsis patients who survived and those who did not (*p < 0.01). (D) Plasma GRP
concentrations were similar, however, between the survivors and nonsurvivors in the SIRS
patient group. (E, F) GRP concentration served as an effective predictor of mortality in
septic patients; a GRP concentration below a cutoff value of 10 pg/mL was associated
with greater incidence of survival (p < 0.01 versus nonsurvival).
tagonism on TNF-α–stimulated RAW
264.7. Treatment with RC-3095 resulted in
a significant decrease in IL-6 titers com-
pared with the corresponding levels in
TNF-α–stimulated RAW 264.7 (Figure 7,
F = 11.16, p < 0.001), suggesting that the
effects of RC-3095 was not solely related
to the inhibition of TLR-4 signaling.
DISCUSSION
In the present study, we demonstrated
that treatment with RC-3095 can decrease
TLR-4 expression and downstream sig-
naling activation in RAW 264.7 cells stim-
ulated by LPS and TNF-α, leading to a
decrease in chemokines and cytokines re-
lease, probably by inhibition of JNK sig-
naling. These results were supported by
our in vivo experiments that showed
lower IL-6 and MCP-1 concentrations in
RC-3095–treated CLP animals. Further-
more, we showed that treatment with
RC-3095 decreased levels of inflamma-
tory cells in BALF, systemic circulation
and peritoneal exudate of CLP  animals.
Our results indicate that administration
of RC-3095 limited the spread of infection
beyond the abdominal compartment,
suggesting that RC-3095 could potentially
prevent the development of the multiple
organ dysfunction  syndrome (36).
There are numerous factors that interact
in the long chain of events from pathogen
recognition to the diversity of host re-
sponses (37,38). Our findings provide
support for the notion that TLR-4 is a par-
ticularly important element of host de-
fense modulated by GRP during sepsis
(23,38). This view is strongly supported
by prior research showing that TLR-4–de-
fective mice do not exhibit failure of neu-
trophil migration to the peritoneal cavity
during polymicrobial sepsis induced by
lethal CLP and, as consequence, are more
resistant to sepsis than controls (11). Fur-
thermore, increased concentration of
mRNA for TLR-4 in lung tissue 3 h after
CLP surgery has been shown to precede
and correlate with death (39). In fact, we
observed a huge decrease on TLR4
mRNA and a slight reduction on protein
levels, suggesting that posttranslational
mechanisms that can eventually modulate
TLR-4 levels are not affected by RC-3095.
This is of major relevance because, al-
though the complete lack of TLR-4 signal-
ing is beneficial in polymicrobial sepsis, it
can have detrimental effects on the basal
immune response to gram-negative bacte-
ria (11); thus, the results presented here
seem to be of greater clinical  significance.
It is well established that immune re-
sponses may be influenced by the nerv-
ous system (40). Studies support that neu-
ropeptides, which regulate the
macrophage response to LPS, affect TLR-4
expression (41) and regulate TLR-4 signal-
ing (42). In this context, and because acti-
vated macrophages have been shown to
secrete GRP (43) and macrophages seem
to be central in the development of sepsis
and septic shock (44), we observed a de-
crease in the expression of TLR-4 mRNA
in RAW 264.7 cells stimulated by LPS
after treatment with RC-3095. Our find-
ings are consistent with recent reports
that increased expression of TLR-2 and
TLR-4 during the early phase of sepsis
correlates with death in CLP animals (39)
and that the downregulation of these re-
ceptors increases survival (11). Further-
more, our observation that RC-3095 in-
hibits upregulation of TLR-4 in
polymicrobial sepsis in lung tissue 6 h
after CLP, leading to a diminution of lung
inflammation, fits with prior research in-
dicating that GRP is present in pulmonary
neuroendocrine cells and may be a media-
tor of acute and chronic lung injury in
bronchopulmonary dysplasia (45). The
findings also fit with the observation that
GRPR antagonism can alleviate alveolar
edema and inflammatory infiltration (22).
During endotoxic shock, a massive
number of neutrophils and other leuko-
cytes accumulate in the lung—a process
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Figure 6. RC-3095 attenuated plasma IL-6
levels in sepsis patients. Twelve patients
with a clinical diagnosis of septic shock
and failure of three or more organs re-
ceived a continuous infusion with RC-3095
(3 mg/kg) over a period of 12 h, and
plasma samples were collected before
and after RC-3095 administration. The 11
patients who did not receive RC-3095
were included as controls. (A, B) ELISA
showed that 12-h infusion of RC-3095 re-
sulted in decreased levels of IL-6 but not IL-
10, respectively (*p < 0.05 for T12 versus T0
RC-3095–treated group; $p < 0.05 for T12
sepsis versus T12 sepsis + RC-3095 [with “T0”
indicating “before RC-3095 administration”
and “T12” “after RC-3095 administration.”].
Figure 7. RC-3095 effects were not solely
related to the inhibition of TLR-4 signaling.
Cells were exposed to TNF-α (Sigma-
Aldrich) 4 h later; RC-3095 (10 ng/mL) was
added for 2 h. Samples from the medium
were collected to determine IL-6 levels.
RC-3095 treatment resulted in a significant
decrease in IL-6 levels compared with the
corresponding levels in TNF-α–stimulated
RAW 264.7 (*p < 0.05 versus control and
$p < 0.05 versus TNF-α).
entirely dependent on TLR-4. Leukocyte
accumulation in the lung is also ob-
served in humans with sepsis (46), where
systemic activation of TLR-4 results in
immense trapping of leukocytes within
lung capillaries (47). One could argue
that the effects of TLR-4 antagonists in
sepsis will lead only to minor effects,
since the TLR-4 activation is extremely
rapid; thus, in the clinical scenario, it
would already be activated by the time
of drug administration. Our data suggest
that, in the CLP, TLR4 is upregulated for
long times after CLP; thus, although
TLR4 activation is extremely rapid, the
repeated (or continuous) activation of
TLR4 in vivo (due to the delay of source
control or antibiotics administration, for
example) can be a target to drugs that
downregulate TLR4 activation. This idea
is supported by septic patient data that
demonstrate an upregulation of several
genes from the TLR4 pathway that per-
sist in the different stages of sepsis devel-
opment (48). Furthermore, neuropeptides
are known to stimulate cytokine produc-
tion in macrophages, lymphocytes and
mast cells, and substance P is reported to
influence LPS-induced production of
proinflammatory cytokines, a mecha-
nism that is abolished by neurokinin-1
(NK-1) receptor blocking (49). Arranz et
al. (50) showed that proinflammatory cy-
tokines can act synergistically, together
with gram-negative bacterial compo-
nents, to upregulate TLR-4 expression.
Thus, it is possible that vasoactive intes-
tinal peptide (VIP)-induced inhibition of
TLR-4 upregulation in inflammatory
models occurs indirectly via suppression
of proinflammatory cytokine production
(50). We propose that GRP may serve an
autocrine/ paracrine role in macrophage
activation during sepsis and/or LPS
stimulation, leading to a modulation of
proinflammatory, but not antiinflamma-
tory, responses (51). In addition, it was
recently demonstrated that GRP can
 directly induce GRPR-mediated neu-
trophil migration (52); thus, complemen-
tary mechanisms of action can be
achieved by the inhibition of GRPR,
which can be beneficial in treating  sepsis.
In addition, we can see that the path-
way activated by TNF-α also appears to
be associated with decreased proinflam-
matory response in severe sepsis caused
by RC-3095 effects, since our findings
show a decrease of IL-6 levels in TNF-α–
stimulated cells when treated with RC-
3095. The TNFR1/R2 pathways share
signaling pathways of TLR-4, resulting in
NF-κB activation (23,46). Thus, it was
suggested that there is an interaction be-
tween GRPR and TLR-4 and TNFR1/R2
pathways, implicating some level of hier-
archy or cooperation between these sig-
naling pathways in the generation of in-
flammation during sepsis. In fact, it was
previously demonstrated that there is an
interaction between GRPR and CXCR2
(51), suggesting that GRPR can be a cen-
tral modulator of immune responses
during sepsis.
CONCLUSION
Our results indicate that the protective
effect of GRPR antagonists can be attrib-
uted to an attenuation of TLR-4 or
TNFR1/R2 signaling. This attenuation
favors neutrophil infiltration, resulting in
decreased bacteremia and thus improv-
ing sepsis outcome. Taken together, the
present results suggest that a GRPR an-
tagonist could be developed as a new al-
ternative therapy for bacterial sepsis.
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